Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates

Historically, neoadjuvant therapy was for patients with locally advanced non-metastatic breast cancer, in whom even mastectomy may not be an option, now it is frequently administered to patients with operable breast cancers, in an effort to avoid mastectomy or improve cosmetic outcomes following surgery or to limit the extent of axillary lymph node removal. Additionally, the response to neoadjuvant therapy and overall risk of recurrence can influence selection of postoperative therapy. Discussions between the surgical oncologist and medical oncologist are therefore important in determining the goals and potential benefits of neoadjuvant/adjuvant therapy for a given patient. By staying up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy, the clinicians will be able to provide appropriate care using a shared decision-making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this program, participants should be able to:

  • Compare and contrast data on the clinical safety and efficacy of neoadjuvant regimens in early stage non-metastatic breast cancer.
  • Recognize key patient and clinical factors that influence selection of systemic neoadjuvant/adjuvant therapy for patients with early stage non-metastatic breast cancer.
  • Discuss clinical data of new and emerging supportive care interventions to improve quality of life of patients undergoing neoadjuvant/adjuvant chemotherapy.
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Exact Sciences
  • Gilead Sciences, Inc.
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Seagen

This activity is supported by independent educational grants from:

  • Daiichi Sankyo 
  • Merck & Co., Inc. 

This activity is supported independent medical education grants from:

  • Organon
  • Pfizer Inc. 
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 

Rachel C. Jankowitz, MD
Abramson Cancer Center at the University of Pennsylvania 

Ami Shah, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University


NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated. 

Rachel C. Jankowitz, MD
Biotheranostics: Scientific Advisor

Ami Shah, MD
AstraZeneca Pharmaceuticals LP: Honoraria
Gilead Sciences, Inc.: Honoraria

Planning Committee and NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated. 

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Biotheronostics: Honoraria; Scientific Advisor
Daiichi-Sankyo co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
ImmunoGen, Inc.: Honoraria; Scientific Advisor
MacroGenics: Scientific Advisor
Puma Biotechnology: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-23-021-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 15, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing